Public articles linked to the same research event.
Nature News A genome-wide association study of 27,885 people using GLP1 receptor agonists identified a missense variant in GLP1R associated with weight-loss efficacy (about 0.76 kg additional weight loss per effect allele), plus GLP1R and GIPR signals for nausea and vomiting (the GIPR association restricted to tirzepatide users), and used these to build combined genetic and non-genetic models that stratify patients by efficacy and side-effect risk in held-out electronic health record data.
A genome-wide association study of 27,885 people using GLP1 receptor agonists identified a missense variant in GLP1R associated with weight-loss efficacy (about 0.76 kg additional weight loss per effect allele), plus GLP1R and GIPR signals for nausea and vomiting (the GIPR association restricted to tirzepatide users), and used these to build combined genetic and non-genetic models that stratify patients by efficacy and side-effect risk in held-out electronic health record data.
A genome-wide association study of 27,885 people using GLP1 receptor agonists identified a missense variant in GLP1R associated with weight-loss efficacy (about 0.76 kg additional weight loss per effect allele), plus GLP1R and GIPR signals for nausea and vomiting (the GIPR association restricted to tirzepatide users), and used these to build combined genetic and non-genetic models that stratify patients by efficacy and side-effect risk in held-out electronic health record data.
A genome-wide association study of 27,885 people using GLP1 receptor agonists identified a missense variant in GLP1R associated with weight-loss efficacy (about 0.76 kg additional weight loss per effect allele), plus GLP1R and GIPR signals for nausea and vomiting (the GIPR association restricted to tirzepatide users), and used these to build combined genetic and non-genetic models that stratify patients by efficacy and side-effect risk in held-out electronic health record data.